CG
FPRX

Clinton Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Clinton Group’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-8,175
Closed -$410K – 1091
2016
Q4 		$410K Sell
8,175
-6,031
-42% -$317K 0.02% 622
2016
Q3 		$746K Sell
14,206
-11,104
-44% -$530K 0.03% 569
2016
Q2 		$1.05M Buy
25,310
+12,618
+99% +$549K 0.05% 465
2016
Q1 		$516K Buy
+12,692
New +$436K 0.03% 612

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Clinton Group's FPRX Position: Q1 2017 in Review

Clinton Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2017, closing a stake of 8,175 shares — an estimated $410K sold.

Clinton Group first reported a position in FPRX in Q1 2016 and held it in 4 quarters. The position peaked at $1.05M in Q2 2016. 157 funds tracked by Wall St. Rank hold FPRX as of Q1 2017.

  • Clinton Group reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Clinton Group sold 8,175 Five Prime Therapeutics, Inc. shares in Q1 2017, an estimated $410K.
  • Clinton Group first reported a position in Five Prime Therapeutics, Inc. in Q1 2016 and held it in 4 quarters.
  • Clinton Group's Five Prime Therapeutics, Inc. position peaked at $1.05M in Q2 2016.
  • 157 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2017.

Based on Clinton Group's 13F filing for Q1 2017, filed 10 May 2017.